文献速递造血干细胞移植与细胞治疗白血病

抗炎性小体人诱导多能干细胞来源髓系衍生抑制细胞改善异种移植物抗宿主病

Inflammasome-resistant IPSC-derived myeloid-derived suppressor cells ameliorate xenogeneic graft-versus-host disease.
PubMed 文献 · Blood · 2025-01-01

本研究开发了从人诱导多能干细胞(iPSC)来源CD34+细胞生成髓系衍生抑制细胞(iMDSCs)的方法,iMDSCs与外周血来源MDSCs形态、表型及抑制功能相似,CD14+亚群抑制功能最强。在脂多糖加三磷酸腺苷刺激下,iMDSCs体外仍保留95%抑制功能。在异种GVHD模型中,iMDSCs显著提高受体生存率且不丧失抗白血病效应。

要点

  • iPSC来源CD34+细胞可生成MDSCs,与PB-MDSCs形态、表型及抑制功能相似。
  • CD14+ iMDSC亚群具有最高抑制功能。
  • iMDSCs在LPS加ATP刺激下体外保留95%抑制功能,与PB-MDSCs形成鲜明对比。

核心结论

  • iMDSCs在异种GVHD模型中显著提高受体生存率且不丧失抗白血病效应,为体外生成的即用型iMDSCs临床转化提供了平台。

研究设计与样本

  • 研究开发了利用人iPSC来源CD34+细胞生成MDSCs的方法,并在体外及异种GVHD模型中进行功能验证。

主要发现

  • 与PB-MDSCs相比,iMDSCs具有相似的形态、表型和抑制功能,其中CD14+ iMDSC亚群抑制功能最高。
  • 与PB-MDSCs形成鲜明对比,iMDSCs在LPS加ATP刺激下体外仍保留95%的抑制功能。
  • 在采用外周血单个核细胞的异种GVHD模型中,iMDSCs显著提高受体生存率且不丧失抗白血病效应。
  • RNA测序和基因敲低研究表明,LPS加ATP处理期间嘌呤代谢酶磷酸甘油酸脱氢酶的维持与iMDSC抗炎性小体特性相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Front-line pharmaceutical interventions for treating acute graft-versus-host disease (GVHD) are not uniformly effective and have toxic side effects. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with potent in vitro and in vivo immunosuppressive functions. Clinical translation of in vitro-generated MDSCs has been limited because of requirements for multiple, high infusion doses, the relatively low yield from peripheral blood-sourced MDSCs (PB-MDSCs), and inconsistent product quality. To circumvent these obstacles, we developed a methodology to generate MDSCs using human induced pluripotent stem cell (iPSC)-derived CD34+ cells. Compared with PB-MDSCs, iPSC-derived MDSCs (iMDSCs) shared similar morphology, phenotype, and suppressive function. We found that the CD14+ iMDSC subset possessed the highest suppressor function. In previous studies, we reported that MDSCs transferred into mice with GVHD lost suppressor function because of inflammasome activation and immature myeloid cell maturation. In striking contrast to human PB-MDSCs, we show herein that iMDSCs retained 95% of suppressor function in vitro despite exposure to lipopolysaccharide (LPS) plus adenosine triphosphate (ATP), which are stimuli that activate the inflammasome via danger-associated molecular patterns released during early posttransplant conditioning and GVHD-induced injury. In an in vivo xenogenic GVHD model with PB mononuclear cells, iMDSCs significantly increased recipient survival without loss of antileukemia effects. iMDSC RNA sequencing and gene knockdown studies revealed that the maintenance of the purine metabolizing enzyme, phosphoglycerate dehydrogenase, during LPS plus ATP treatment, was linked to iMDSC inflammasome resistance. Taken together, these findings provide a platform for translating in vitro-generated, off-the-shelf iMDSCs into the clinic for suppressing a spectrum of adverse immune responses, including GVHD.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ma L, Koehn B, Zaiken M, et al. Inflammasome-resistant IPSC-derived myeloid-derived suppressor cells ameliorate xenogeneic graft-versus-host disease. Blood. 2025. PMID: 40700578. doi:10.1182/blood.2025028562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。